GCTK vs MRNA · P/E 0.1, $4.1M cap vs rev $145.0M
GlucoTrack Inc (GCTK) versus Moderna Inc (MRNA) — a side-by-side from cached financials, not a winner call.
GlucoTrack Inc (GCTK) is a medical instruments & supplies company listed on US.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stéphane Bancel M.B.A..
GCTK does not have a complete income-statement cache yet.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
GCTK currently screens at market cap $4.1M and trailing P/E 0.1. MRNA currently screens at market cap $24.52B.
Not investment advice. Open the GCTK and MRNA stock pages for the full models.
Not investment advice.